United States: FDA Issues Draft Guidance Eliminating Regulatory Controls On Medical Device Data Systems, Imaging Storage Devices, And Imaging Communications Devices

On June 20, 2014, the United States Food and Drug Administration (FDA) issued a draft guidance document announcing that the agency does not intend to enforce the general regulatory controls applicable to medical device data systems (MDDSs), medical image storage devices, and medical image communication devices, due to the low risks posed by such devices and their importance in promoting digital health. This draft guidance effectively exempts these devices from compliance with any FDA regulatory requirements. FDA will accept comments on the draft guidance through August 25, 2014. 

This surprising about-face suggests continued evolution in FDA's approach to regulating medical software.

FDA Regulations Classifying Medical Device Data Systems, Medical Image Storage Devices, and Medical Image Communications Devices

In the 1990s, FDA began in earnest to address the rapidly developing electronic data communications and storage technologies widely used in healthcare delivery. One key action was the issuance of guidance and later regulations addressing technologies used to store, transmit, copy, view, and process digital radiology images. After examining the range of devices used to handle such images, FDA established five classifications of radiology imaging devices. Two of these device types – medical image storage devices and medical image communications devices – were classified as Class I, 510(k)-exempt devices subject only to "general controls" such as establishment registration, device listing, postmarket reporting of adverse events, and the Quality System Regulation (QSR). In the final rule, FDA emphasized that general controls, "particularly the good manufacturing practices requirements" of the QSR, were sufficient to provide reasonable assurance of the safety and effectiveness of the two Class I, 510(k)-exempt device types. 1

More than ten years later, FDA adopted a similar approach with respect to devices that had become ubiquitous in the hospital environment: software and associated hardware used to store and transmit electronic data obtained from other medical devices. Through a rulemaking process initiated in 2008 and completed in 2011, FDA defined an MDDS as a device used for the electronic transfer, storage, conversion, or display of medical device data. The carefully circumscribed definition excluded devices that control or alter functions or parameters of any connected medical devices or that are intended to be used in connection with active patient monitoring. Examples of MDDSs include devices that collect and store data from glucose meters for future use or that transfer laboratory results for future use at a nursing station. The 2011 final rule established a new Class I, 510(k)-exempt classification, but did not exempt this device type from general regulatory controls. Manufacturers of such devices were required to register with FDA as medical device manufacturers and list their commercially distributed devices, but were given more than a year, until April 1, 2012, to comply with the QSR and adverse event reporting requirements. As with radiology imaging devices, FDA emphasized the importance of QSR compliance in assuring the safety and effectiveness of these devices. 2 FDA reaffirmed its view of the regulatory controls applicable to MDDSs as recently as September 25, 2013, in the Mobile Medical Apps guidance (MMA Guidance), which contained several examples describing the application of device regulations to MDDSs.

2014 Draft Guidance

In the recently released draft guidance, FDA states that, after gaining additional experience with MDDSs since the 2011 classification regulation, it has determined that these devices pose low risk to the public and that it is unnecessary to enforce compliance with regulatory controls for this type of device. Similarly, FDA states that it is unnecessary to enforce regulatory controls that apply to medical image storage devices and medical image communications devices. For all of these device types, the draft guidance would release manufacturers from the burdens of complying with general controls, including the QSR requirements FDA previously emphasized. Together with the existing regulatory exemptions of these devices from compliance with 510(k) premarket notification requirements, these devices would effectively be completely unregulated. 

The draft guidance also proposes to adopt conforming changes to the MMA Guidance, modifying certain examples of regulated mobile apps and stating explicitly that FDA will exercise enforcement discretion with regard to mobile apps that meet the definition of a MDDS.

Implications of the Draft Guidance

The draft guidance represents a significant change in policy just three years after FDA completed a multi-year rulemaking process for MDDSs. It appears to reflect an evolving FDA view of the agency's role in regulating low-risk digital health software, and is consistent with other recent FDA pronouncements generally favoring industry self-regulatory standards, public-private partnerships, and other non-regulatory mechanisms for assuring the safety and effectiveness of such products. Ropes & Gray previously commented on this development in our  Alert on FDA's final guidance on Mobile Medical Apps. This general approach was also evident in the April 2014 Health IT Report issued jointly by the FDA, Federal Communications Commission, and the HHS Office of the National Coordinator for Health Information Technology. 

Manufacturers of MDDSs that already invested in processes to comply with general controls may perceive this FDA policy change as unfairly favoring competitors that had not made such investments. Nonetheless, manufacturers that have come into compliance with the QSR may conclude that such compliance, although no longer required, will continue to benefit them by ensuring traceability of design, helping identify necessary product corrections and improvements, and controlling bug fixes and other product changes.

Companies that design, produce, or distribute medical software should carefully review their products' technological characteristics, labeling, and promotional materials to determine whether they fall within the device classifications affected by FDA's draft guidance.


1. 63 Fed. Reg. 23385, 23385 (Apr. 29, 1998).

2. 76 Fed. Reg. 8637, 8639 (Feb. 15, 2011).

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Similar Articles
Relevancy Powered by MondaqAI
In association with
Related Topics
Similar Articles
Relevancy Powered by MondaqAI
Related Articles
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Mondaq Free Registration
Gain access to Mondaq global archive of over 375,000 articles covering 200 countries with a personalised News Alert and automatic login on this device.
Mondaq News Alert (some suggested topics and region)
Select Topics
Registration (please scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions

Mondaq.com (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of www.mondaq.com

To Use Mondaq.com you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.


The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.


Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions